# AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00022282** · PHASE2 · COMPLETED · sponsor: **AEterna Zentaris**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** shark cartilage extract AE-941

## Key facts

- **NCT ID:** NCT00022282
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022282, "AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00022282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*